Moderna shares soar after mRNA cancer vaccine trial succeeds

Moderna shares more than doubled in early trading on Wednesday, August 19, 2026, after the company and its partner Merck announced that their personalized mRNA cancer vaccine, intismeran, met its primary goal in a large-scale Phase 3 clinical trial for melanoma.